Brown, Karen T.
Mayo Clinic
Memorial Sloan Kettering Cancer Center
Citations 2
PHOCUS: A phase 3 randomized, open-label study comparing the oncolytic immunotherapy Pexa-Vec followed by sorafenib (SOR) vs SOR in patients with advanced hepatocellular carcinoma (HCC) without prior systemic therapy.
Galle, Peter R. , Luca, Angelo , Pelusio, Adina, Agathon, Delphine , Lusky, Monika, Breitbach, Caroline J. , Galle, Peter Robert , Abou‐Alfa, Ghassan K. , Chao, Yee , Brown, Karen T. , Heo, Jeong , Borad, Mitesh J. , Burke, James, Qin, Shukui
Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: TPS4146-TPS4146
A multicenter pilot study of nivolumab (NIVO) with drug eluting bead transarterial chemoembolization (deb-TACE) in patients (pts) with liver limited hepatocellular carcinoma (HCC).
Tan, Benjamin , Reiss, Kim Anna, Mody, Kabir , Khalil, Daniel, Nadolski, G. , Giardina, Joseph Daniel , Capanu, Marinela , Bradley, Mikaela , Boussayoud, Chayma, Valentino, Emily , Harding, James J. , Erinjeri, Joseph P. , Yarmohammadi, Hooman , Gian, Richard Kinh , Merghoub, Taha , Jarnagin, William R. , Soulen, Michael C , Brown, Karen T. , Abou‐Alfa, Ghassan K.
Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: TPS4146-TPS4146